- Home
- DEA vs SGP Comparison
DEA vs SGP Comparison
Compare DEA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | SGP |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 932.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | DEA | SGP |
|---|---|---|
| Price | $23.79 | $21.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $23.49 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 318.1K | 51.9K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 7.77% | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $336,099,000.00 | N/A |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $1,197.00 | ★ N/A |
| Revenue Growth | ★ 11.27 | N/A |
| 52 Week Low | $20.56 | $20.15 |
| 52 Week High | $24.94 | $30.56 |
Technical Indicators
Market Signals| Indicator | DEA | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 36.44 |
| Support Level | $23.49 | N/A |
| Resistance Level | $23.76 | $26.29 |
| Average True Range (ATR) | 0.44 | 1.54 |
| MACD | 0.05 | -0.28 |
| Stochastic Oscillator | 82.73 | 2.59 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.